-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KcaNt9aVdqY911CyVco2I1y9bF8I3EjP/SGg9AssAjPt0/cqOXA4oT+a9WTumMAK
 TlmNnQCCgnVn9BVdG1MPxQ==

<SEC-DOCUMENT>0000927946-04-000179.txt : 20040820
<SEC-HEADER>0000927946-04-000179.hdr.sgml : 20040820
<ACCEPTANCE-DATETIME>20040820171940
ACCESSION NUMBER:		0000927946-04-000179
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040819
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20040820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		04989661

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>basform8k.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC. 8K
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>August 19, 2004</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u>Indiana</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
0-23357</u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
35-1345024</u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
2701 Kent Avenue<br>
<u>West Lafayette, Indiana</u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u>47906-1382</u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
(765) 463-4527</u></font></TD></TR>
<TR VALIGN=top>
<TD>&nbsp;</TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>

<PAGE>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2> The
information in this Form 8-K is being furnished and shall not be deemed
&#147;filed&#148; for the purpose of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section.
The information in this Form 8-K shall not be incorporated by reference into any
registration statement or other document pursuant to the Securities Act of 1933,
as amended.</FONT></P>

<!-- MARKER FORMAT-SHEET="Indented Head Left" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits
</font></P>
<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bioanalytical Systems, Inc. press
release, issued August 19, 2004.</font></P>


<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
On August 19, 2004, Bioanalytical Systems, Inc. (the "Company") issued a press
release announcing that Gayl W. Doster has been elected to its Board of
Directors.</font></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
The full text of the press release is furnished as exhibit 99.1 to this Form
8-K.</FONT></P>


<PAGE>




<!-- MARKER FORMAT-SHEET="ARTICLE bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SIGNATURES</FONT></H1>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>


<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;August 19, 2004</FONT></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc.<BR>
<BR>
<BR>
<BR>

By:&nbsp;&nbsp;/s/ Michael R. Cox<hr>
Michael R. Cox<BR>
VP-Finance, Chief Financial Officer and<BR>
Treasurer
</FONT></Td>
</TR>
</TABLE>
<BR>
<PAGE>


<!-- MARKER FORMAT-SHEET="Heading Center Bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit Index</U></FONT></H1>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10%><div align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit No.</U><BR>
<BR>
99.1</FONT></div></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description</U><BR>
<BR>
Bioanalytical Systems, Inc. press release, issued August 19, 2004.
</FONT></TD>
</TR>
</TABLE>
<BR>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>pressrelease991.htm
<DESCRIPTION>EXHIBIT 99.1 - PRESS RELEASE
<TEXT>



<HTML>
<HEAD>
<TITLE>Press Release - Exhibit 99.1</TITLE>
</HEAD>
<BODY>

<BR>
<BR>

<P align=center><FONT FACE="Times New Roman, Times, Serif" size=2>
<B>Bioanalytical Systems Elects Gayl W. Doster to Board of Directors</B>
</font></P>
<BR>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
WEST LAFAYETTE, Ind., August 19, 2004 Bioanalytical Systems, Inc. (Nasdaq:
<U>BASI</U> - <U>NEWS</U>) announced today that Gayl W. Doster has been elected
 to its Board of Directors.  Mr. Doster joins as an independent director.
</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Mr. Doster is the former President of Sigma Micro Corporation, President and
COO of Brooks Drug, and Executive VP and CFO of Hook-SupeRx, Inc.  He is
currently a member of the Board of Directors of Meta Group, Inc. and has
served on the Board of Capital Properties.
</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Mr. Doster was inducted into the American Institute of Certified Public
Accountants Business and Industry Hall of Fame in 2000 recognizing more than
three decades of outstanding service.  He has also been named an Outstanding
Member in Industry of the Indiana CPA Society where he currently serves as
Chair of the Joint Task Force on Regulation.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
BASi Chairman Dr. Peter T. Kissinger commented, "Gayl's enthusiasm to join BASi
 as we evolve into something much bigger is gratifying.  He brings operating
and administrative muscle to our already technically excellent team.  We are
all looking forward to his insight and counsel."</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
In connection with his election as a director, BASi granted Mr. Doster an
option to purchase 5,000 BASi Common Shares at the per-share market price at
the close of business on August 19, 2004.</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development and
medical device companies.  The company focuses on developing innovative
services and products that increase efficiency and reduce the cost of taking a
new drug to market.  Visit <U>http://www.bioanalytical.com</U> for more about
BASi.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
This release contains forward-looking statements that are subject to risks and
uncertainties including, but not limited to, risks and uncertainties related to
 the development of products and services, changes in technology, industry
standards and regulatory standards, and various market and operating risks
detailed in the company's filings with the Securities and Exchange Commission.
</FONT></P>
<BR>
<BR>
<P align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE="2">
<HR ALIGN=LEFT WIDTH=200>
<I>Contact:</I><BR>
&nbsp;&nbsp;&nbsp;&nbsp;Bioanalytical Systems, Inc.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;Alice Schwind, 765-497-8458<BR>
&nbsp;&nbsp;&nbsp;&nbsp;<U>alice@bioanalytical.com</U><BR>
</FONT> </P>

</BODY>
</HTML>



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
